Bavarian Nordic Receives EMA Approval Of Mpox Vaccine For Adolescents; Approval Extends Current Marketing Authorization To Include Adolescents 12 To 17 Years Of Age; Clinical Trial To Assess Immunogenicity, Safety Of MVA-BN In Children 2-12 Years Is Expected To Start Next Month
Portfolio Pulse from Benzinga Newsdesk
Bavarian Nordic has received EMA approval to extend the marketing authorization of its Mpox vaccine to adolescents aged 12 to 17. A clinical trial for children aged 2 to 12 is expected to start next month.
September 19, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bavarian Nordic's Mpox vaccine has been approved by the EMA for adolescents aged 12-17, potentially expanding its market reach. A clinical trial for younger children is also planned.
The EMA approval allows Bavarian Nordic to market its Mpox vaccine to a new age group, potentially increasing sales and market penetration. The upcoming clinical trial for younger children could further expand its market if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
VGK, a European ETF, may see indirect effects from Bavarian Nordic's EMA approval due to its exposure to European healthcare stocks.
VGK, being a European ETF, might experience indirect benefits from the approval of Bavarian Nordic's vaccine, as it includes European healthcare stocks. However, the direct impact is limited.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20